According to the results of the early study, published simultaneously in the New England Journal of Medicine, 92% of patients ...

Patients with some gastrointestinal tumors were able to be treated with immunotherapy drugs alone and avoid surgery, ...

A New England Journal of Medicine study published April 27 found success in administering dostarlimab, an immunotherapy drug, ...

"We found that some cancer types responded extremely well to the immunotherapy, including colon and stomach cancer," ...

Some people with early stage cancers may be able to skip surgery after being treated with the immunotherapy drug dostarlimab, ...

For a limited group of cancer patients who have solid tumors in the stomach, rectum, esophagus and other organs, an ...

Dostarlimab effectively eliminates the need for surgery in patients with advanced mismatch repair-deficient (dMMR) tumors, ...

A new, small cancer study may give hope to patients with solid tumors in the stomach, esophagus or rectum. Read more trending ...

Generally, the standard treatment for solid tumors is surgery. However, a recent study from New York City-based Memorial Sloan Kettering Cancer Center found immunotherapy can effectively treat these ...

No other drugs, except for the immunotherapy treatment, dostarlimab ... while as much as 30% of endometrial cancer has the mutation, NBC News reported. Cleveland Clinic gastrointestinal medical ...